References
- Grabowski H, Vernon J. Longer patents for lower imitation barriers: the 1984 drug act. Amer Econ Rev 1986;76:195-8
- Berndt E. Pharmaceuticals in U.S. health care: determinants of quantity and price. J Econ Perspect 2002;16:45-66
- Science and Data Policy, Assistant Secretary for Planning and Evaluation. Expanding the Use of Generic Drugs. Washington, DC. 2010. Available at: http://aspe.hhs.gov/sp/reports/2010/genericdrugs/ib.pdf. Accessed May 15, 2013
- IMS Institute for Healthcare Informatics. Declining Medicine Use and Costs: For Better or Worse? Parsippany, NJ. 2013. Available at: http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22a/?vgnextoid=5b21ee0a8e631410VgnVCM10000076192ca2RCRD. Accessed May 15, 2013
- The Congress of the United States, Congressional Budget Office. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Washington, DC. 1998. Available at: http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/6xx/doc655/pharm.pdf. Accessed May 15, 2013
- Grabowski H, Kyle M. Generic competition and market exclusivity periods in pharmaceuticals. Manage Decis Econ 2007;28:491-502
- Grabowski H, Kyle M, Mortimer R, et al. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act. Health Affairs 2011;30:2157-66
- U.S. Food and Drug Administration. Abbreviated New Drug Application and Generics. 2013:1-42. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM293268.pdf. Accessed May 15, 2013
- Panattoni LE. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. J Health Econ 2011;30:126-45
- Smith K, Gleklen K. Generic drugmakers will challenge patents even when they have a 97% chance of losing: The FTC Report that K-Dur Ignored. Boston, MA: CPI Antitrust Chronicle, 2012. www.competitionpolicyinternational.com/generic-drugmakers-will-challenge-patents-even-when-they-have-a-97-chance-of-losing-the-ftc-report-that-k-dur-ignored/. Accessed October 3, 2013
- Greene A, Steadman DD. Analyzing Litigation Success Rates. Pharmaceuticals. 2010;(212):1-24. http://www.aipla.org/committees/committee_pages/FDA/CommitteeDocuments/MeetingMaterials/2010SpringMeeting/AnalyzingLitigationSuccessRates.pdf. Accessed May 15, 2013
- Glass G. Legal defenses and outcomes in Paragraph IV Patent Litigation. J Generic Med 2013;10:4-13